Abstract: A method for treating a multiple sclerosis is provided. The method includes administering a composition containing a plurality of mesenchymal stem cells to a subject in need for a treatment of the multiple sclerosis, in which each of the mesenchymal stem cells expresses insulin-like growth factor 1 receptors.

Abstract: An immunomagnetic nanocapsule includes a core, a shell and an outer layer. The shell is formed by a complex, and the complex is fabricated by a combination of fucoidan, oxidized dextran, and a plurality of superparamagnetic iron oxide nanoparticles via a hydrophobic interaction. The core is encapsulated in the shell. The outer layer includes at least one antibody immobilized to outside of the shell to form the outer layer, wherein the antibody is an immune checkpoint inhibitor and/or a T cell expansion antibody.

Abstract: The present disclosure relates to a bicyclic compound, a pharmaceutical composition thereof, and its novel use. More particularly, the present disclosure relates to the bicyclic compound according to Formula I or Formula II, the pharmaceutical composition for treating a stroke, and the use of the bicyclic compound treating the stroke.

Abstract: A composition including adult pluripotent olfactory stem cells is provided. The adult pluripotent olfactory stem cells are obtained by culturing a cell mixture from an olfactory tissue of a mammal in media containing growth factors and then isolating cells which express B-lymphoma moloney murine leukemia virus insertion region-1 (Bmi-1).

Abstract: A method for enhancing an insulin like growth factor 1 receptor expression of a mesenchymal stem cell is provided. The method includes culturing a plurality of mesenchymal stem cells expressing insulin-like growth factor 1 receptors in media containing human cord blood serum to enhance the insulin like growth factor 1 receptor expression of the mesenchymal stem cells.

Abstract: The present disclosure relates to a bicyclic compound, a pharmaceutical composition thereof, and its novel use. More particularly, the present disclosure relates to the bicyclic compound according to Formula I or Formula II, the pharmaceutical composition for treating a stroke, and the use of the bicyclic compound treating the stroke.

Abstract: The present invention is related to novel 20-sulfonylamidine derivatives of camptothecin (1), method of synthesizing the same, and use thereof as an antitumor agent, for examples an antitumor agent for treating nasopharyngeal, lung, breast or prostate cancer.

Abstract: A mesenchymal stem cell is provided. The mesenchymal stem cell that expresses an insulin-like growth factor 1 receptor have been cultured in media containing human cord blood serum and isolated, such that an insulin-like growth factor 1 receptor expression is enhanced in the isolated mesenchymal stem cells.

Abstract: The present disclosure provides methods for the treatment of neurological diseases/disorders using neural stem cells (NSCs) obtained from a spinal cord tissue. The methods may include the use of a NSC population to treat a neurological disease/disorder of the brain. Such methods may include introducing exogenously cultured and expanded NSCs into the brain, which differentiate into neurons capable of integrating in vivo into the brain tissue in a sufficient manner to ameliorate the symptoms associated with the neurological disease/disorder.

Abstract: The present invention is related to novel 20-sulfonylamidine derivatives of camptothecin (1), method of synthesizing the same, and use thereof as an antitumor agent, for examples an antitumor agent for treating nasopharyngeal, lung, breast or prostate cancer.

Abstract: Methods of treating brain ischema or hypoxia by using an inhibitor of cysteine-glutamate transporter (i.e. system xc?) is provided. The inhibitor includes sorafenib and a derivative thereof, erastin, and suifasalazine. These inhibitors can effectively decrease a concentration of extracellular glutamate, so that excitotoxicity to central nervous system (CNS) and a cortical infarct volume in brains can be reduced.

Abstract: A magnetic separation unit is provided, including a first member made of non-magnetic materials comprising a trench extending within the first member and a second member made of magnetic materials including a protrusion portion protruding over a surface of the second member, wherein the first member connects the second member such that the trench functions as a fluid channel formed between the first and second members, and the protrusion portion of the second member is contained by the trench of the first member.

Abstract: A magnetic separation device is provided, including a first magnetic field unit and a first separation unit disposed at a side of the first magnetic field unit. The first magnetic field unit includes a first magnetic yoke having opposite first and second surfaces, and a plurality of first magnets respectively disposed over the first and second surfaces, wherein the same magnetic poles of the plurality of first magnets face the first magnetic yoke. The first separation unit includes a body made of non-magnetic materials and a continuous piping disposed in the body, including at least one first section and at least one second section, wherein at least one second section is perpendicular to at least one first section, and at least one second section is adjacent to, and in parallel to a side of the first magnetic yoke not in contact with the plurality of first magnets.

Abstract: Disclosed is a cultured pluripotent animal cell that is prepared from nasal polyps. Also disclosed are methods for making the cell and methods of treating a brain tissue damage or of promoting cerebral angiogenesis, cerebral neurogenesis, stem cell homing to the brain, neurotrophic factor expression in the brain.

Abstract: A magnetic separation unit is provided, including a first member made of non-magnetic materials comprising a trench extending within the first member and a second member made of magnetic materials including a protrusion portion protruding over a surface of the second member, wherein the first member connects the second member such that the trench functions as a fluid channel formed between the first and second members, and the protrusion portion of the second member is contained by the trench of the first member.

Abstract: The present disclosure provides methods for the treatment of neurological diseases/disorders using neural stem cells (NSCs) obtained from a spinal cord tissue. The methods may include the use of a NSC population to treat a neurological disease/disorder of the brain. Such methods may include introducing exogenously cultured and expanded NSCs into the brain, which differentiate into neurons capable of integrating in vivo into the brain tissue in a sufficient manner to ameliorate the symptoms associated with the neurological disease/disorder.

Abstract: The invention relates to the treatment of chronic stroke, traumatic brain injury, and neurodegenerative disorders using umbilical cord blood cells.

Abstract: A magnetic separation device is provided, including a first magnetic field unit and a first separation unit disposed at a side of the first magnetic field unit. The first magnetic field unit includes a first magnetic yoke having opposite first and second surfaces, and a plurality of first magnets respectively disposed over the first and second surfaces, wherein the same magnetic poles of the plurality of first magnets face the first magnetic yoke. The first separation unit includes a body made of non-magnetic materials and a continuous piping disposed in the body, including at least one first section and at least one second section, wherein at least one second section is perpendicular to at least one first section, and at least one second section is adjacent to, and in parallel to a side of the first magnetic yoke not in contact with the plurality of first magnets.

Abstract: A cultured pluripotent animal cell that is CD13+, CD90+, and CD117?. Also disclosed are methods for making the cell and methods of treating a brain tissue damage and increasing the expression level of a neuraltrophic factor in a subject.

Abstract: Disclosed are methods for conditioning stems cells and using the conditioned stems cells for treating brain tissue damage.